ArticleCanadian liver journal2026
The predictive role of ammonia in liver-related decompensation and mortality in patients with compensated cirrhosis: A retrospective cohort study.
Article in Canadian liver journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Liver cirrhosis may present in different stages with distinct prognoses. Commonly used models for predicting liver-related decompensation and mortality have several limitations. Ammonia was proposed as a possible alternative or complementary tool. Our primary objective was to explore the predictive role of plasma ammonia levels regarding liver-related outcomes. Our secondary aim was to validate a new measure that corrects baseline ammonia levels to the upper limit of normal (AMM-ULN) as a predictor of liver-related outcomes. Methods: In this retrospective single-centre study, 278 patients with cirrhosis and an ammonia measurement were included. Relevant outcomes (liver-related decompensation and mortality) were evaluated in the compensated and decompensated groups, and AMM-ULN was assessed as a predictor. Results: Plasma ammonia levels and AMM-ULN were predictors of hepatic decompensation (hazard ratio [HR] 1.453, 95% CI 1.085-1.945, Conclusions: Both ammonia levels and AMM-ULN were predictors of hepatic decompensation and liver-related mortality in compensated patients at 12 months of follow-up.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.